表紙SALE
市場調查報告書
商品編碼
1024098

非何杰金氏淋巴瘤 (NHL) 治療藥的市場預測、競爭趨勢、成長機會 (∼2026年): 治療區分、細胞型、藥物類型、通路、各地區

Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy, By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球非何杰金氏淋巴瘤 (NHL) 治療藥的市場規模在預測期間內 10.02%的年複合成長率發展,成長到2026年146億8931萬美元的規模。

對創新的藥物和新技術的需求高漲,診斷技術的提高,標準的醫藥品的專利到期等要素預計促進該市場的成長。還有廣泛的R&D活動,美國FDA對慢性淋巴性白血病治療藥的認證也預計成為市場進一步成長的要素。

本報告提供全球非何杰金氏淋巴瘤 (NHL) 治療藥的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,客戶的迴響分析,臨床試驗趨勢,市場規模的變化、預測,各治療區分、細胞型、藥物類型、銷售管道的明細,各地區、主要國家的詳細分析,競爭環境,主要企業簡介等彙整資訊。

第1章 產品概要

第2章 調查手法

第3章 COVID-19的影響

第4章 客戶的迴響

第5章 摘要整理

第6章 全球市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各治療種類
      • 免疫療法
      • 標靶治療
      • 化療
      • 幹細胞移植
      • 其他
    • 各細胞型
      • B細胞淋巴瘤
      • T細胞淋巴瘤
    • 各藥物類型
      • Revlimid
      • Rituxan
      • KEYTRUDA
      • Imbruvica
      • Opdivo
      • 其他
    • 各銷售管道
      • 醫院藥局
      • 零售藥局
      • 線上藥局
      • 其他
    • 各企業
    • 各地區
  • 產品市場地圖

第7章 北美市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
  • 各國分析

第8章 歐洲市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
  • 各國分析

第9章 亞太地區市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
  • 各國分析

第10章 南美市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
  • 各國分析

第11章 中東、非洲市場分析、預測

  • 市場規模、預測
  • 市場佔有率、預測
  • 各國分析

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢

第14章 臨床試驗分析

第15章 競爭情形

  • 競爭預測
  • 企業簡介
    • AstraZeneca PLC
    • Baxter International Inc.
    • Bayer AG
    • Novartis AG
    • Eli Lilly and Company.
    • Spectrum Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol Myers Squibb Company
    • GlaxoSmithKline PLC
    • Janssen Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Sanofi S.A.
    • Merck & Co., Inc.
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.

第16章 策略性建議

第17章 關於本公司、免責聲明

目錄
Product Code: 5113

Global Non-Hodgkin Lymphoma (NHL) therapeutics market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% during the forecast period, owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin's lymphomas (NHL). Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for global Non-Hodgkin Lymphoma (NHL) therapeutics market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration's approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.

Non-Hodgkin's lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body's immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.

Global Non-Hodgkin Lymphoma (NHL) therapeutics market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them. In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas. B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.

Regionally, North America dominated the global Non-Hodgkin Lymphoma (NHL) therapeutics market in 2020 and is further expected to hold its dominance during the forecast period. High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market. However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.

Major companies operating in global Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc., among others. The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin's lymphoma therapeutics market. Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of global Non-Hodgkin Lymphoma (NHL) Therapeutics market from 2016 to 2020.
  • To estimate and forecast the market size of global Non-Hodgkin Lymphoma (NHL) therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global Non-Hodgkin Lymphoma (NHL) Therapeutics market based on type of therapy, cell type, drug type, distribution channel, company and regional distribution from 2021 to 2026 and growth rate until 2026.
  • To identify drivers and challenges for global Non-Hodgkin Lymphoma (NHL) therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
  • To identify and analyze the profile of leading players operating in the global Non-Hodgkin Lymphoma (NHL) therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global Non-Hodgkin Lymphoma (NHL) therapeutics market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to Non-Hodgkin Lymphoma (NHL) therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as Non-Hodgkin Lymphoma (NHL) Therapeutics manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global Non-Hodgkin Lymphoma (NHL) therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Stem Cell Transplant
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:

  • B-cell Lymphomas
  • T-cell Lymphomas

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:

  • Revlimid
  • Rituxan
  • Keytruda
  • Imbruvica
  • Opdivo
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Unmet Needs & Challenges
  • 5.3. Factors Influencing Drug Purchase

6. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
    • 6.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
    • 6.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 6.2.5. By Company (2020)
    • 6.2.6. By Region
  • 6.3. Product Market Map

7. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Therapy
    • 7.2.2. By Cell Type
    • 7.2.3. By Drug Type
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Therapy
        • 7.3.1.2.2. By Cell Type
        • 7.3.1.2.3. By Drug Type
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Therapy
        • 7.3.2.2.2. By Cell Type
        • 7.3.2.2.3. By Drug Type
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Therapy
        • 7.3.3.2.2. By Cell Type
        • 7.3.3.2.3. By Drug Type
        • 7.3.3.2.4. By Distribution Channel

8. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Therapy
    • 8.2.2. By Cell Type
    • 8.2.3. By Drug Type
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Therapy
        • 8.3.1.2.2. By Cell Type
        • 8.3.1.2.3. By Drug Type
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Therapy
        • 8.3.2.2.2. By Cell Type
        • 8.3.2.2.3. By Drug Type
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Therapy
        • 8.3.3.2.2. By Cell Type
        • 8.3.3.2.3. By Drug Type
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Therapy
        • 8.3.4.2.2. By Cell Type
        • 8.3.4.2.3. By Drug Type
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Therapy
        • 8.3.5.2.2. By Cell Type
        • 8.3.5.2.3. By Drug Type
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Therapy
    • 9.2.2. By Cell Type
    • 9.2.3. By Drug Type
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Therapy
        • 9.3.1.2.2. By Cell Type
        • 9.3.1.2.3. By Drug Type
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Therapy
        • 9.3.2.2.2. By Cell Type
        • 9.3.2.2.3. By Drug Type
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Therapy
        • 9.3.3.2.2. By Cell Type
        • 9.3.3.2.3. By Drug Type
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type of Therapy
        • 9.3.4.2.2. By Cell Type
        • 9.3.4.2.3. By Drug Type
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type of Therapy
        • 9.3.5.2.2. By Cell Type
        • 9.3.5.2.3. By Drug Type
        • 9.3.5.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Therapy
    • 10.2.2. By Cell Type
    • 10.2.3. By Drug Type
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Therapy
        • 10.3.1.2.2. By Cell Type
        • 10.3.1.2.3. By Drug Type
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Therapy
        • 10.3.2.2.2. By Cell Type
        • 10.3.2.2.3. By Drug Type
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Therapy
        • 10.3.3.2.2. By Cell Type
        • 10.3.3.2.3. By Drug Type
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type of Therapy
    • 11.2.2. By Cell Type
    • 11.2.3. By Drug Type
    • 11.2.4. By Distribution Channel
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type of Therapy
        • 11.3.1.2.2. By Cell Type
        • 11.3.1.2.3. By Drug Type
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type of Therapy
        • 11.3.2.2.2. By Cell Type
        • 11.3.2.2.3. By Drug Type
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type of Therapy
        • 11.3.3.2.2. By Cell Type
        • 11.3.3.2.3. By Drug Type
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Clinical Trial Analysis

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Players Profiled (Leading Companies)
    • 15.2.1. AstraZeneca PLC
    • 15.2.2. Baxter International Inc.
    • 15.2.3. Bayer AG
    • 15.2.4. Novartis AG
    • 15.2.5. Eli Lilly and Company.
    • 15.2.6. Spectrum Pharmaceuticals, Inc.
    • 15.2.7. Teva Pharmaceutical Industries Ltd.
    • 15.2.8. Bristol Myers Squibb Company
    • 15.2.9. GlaxoSmithKline PLC
    • 15.2.10. Janssen Pharmaceuticals, Inc.
    • 15.2.11. F. Hoffmann-La Roche Ltd
    • 15.2.12. Sanofi S.A.
    • 15.2.13. Merck & Co., Inc.
    • 15.2.14. Takeda Pharmaceutical Company Limited
    • 15.2.15. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

List of Figures

  • Figure 1: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 3: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 4: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 5: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 6: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Company, 2020
  • Figure 7: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Region, By Value, 2016-2026F
  • Figure 8: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Product Market Map, By Value, 2016-2026F
  • Figure 9: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 10: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 11: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 12: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 13: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 14: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 15: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 16: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 17: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 18: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 19: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 20: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 21: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 22: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 23: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 24: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 25: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 26: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 27: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 28: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 29: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 30: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 31: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 32: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 33: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 34: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 35: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 36: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 37: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 38: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 39: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 40: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 41: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 42: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 43: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 44: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 45: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 46: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 47: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 48: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 49: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 50: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 51: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 52: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 53: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 54: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 55: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 56: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 57: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 58: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 59: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 60: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 61: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 62: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 63: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 64: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 65: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 66: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 67: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 68: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 69: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 70: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 71: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 72: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 73: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 74: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 75: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 76: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 77: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 78: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 79: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 80: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 81: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 82: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 83: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 84: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 85: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 86: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 87: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 88: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 89: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 90: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 91: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 92: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 93: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 94: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 95: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 96: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 97: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 99: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 100: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 101: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 102: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 103: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 104: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 105: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 106: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 107: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 108: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 109: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 110: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 111: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 112: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 113: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 114: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 115: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 116: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 117: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
  • Figure 118: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 119: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 120: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 121: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 122: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 123: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 124: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 125: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 126: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 127: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 128: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 129: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
  • Figure 130: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
  • Figure 131: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
  • Figure 132: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F